Global pharmaceutical behemoth Pfizer announced disappointing results at the San Antonio Breast Cancer Symposium, USA, on Friday from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
These data showed that women who switched to Aromasin (exemestane tablets) after 2.5 years of tamoxifen experienced a 19% reduction in risk of breast cancer recurrence (HR=0.81 95% CI (0.71, 0.92); p<0.001) compared to those who continued on tamoxifen for a full five years of treatment. >
Separately, results from the Tamoxifen, Exemestane, Adjuvant, Multicenter (TEAM) study did not show a difference in disease free survival (DFS) in women who took Aromasin for five years compared to those who switched from tamoxifen to Aromasin after two to three years (HR=0.97 (95% CI 0.88-1.08); P=0.604). However, the company said that data continue to underscore the benefits of Aromasin for postmenopausal women with hormone-receptor positive/unknown early breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze